A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Naïve Patients with Moderately-to-Severely Active Crohn’s Disease [SEAVUE]
- Moore, Gregory (Primary Chief Investigator (PCI))
Project: Research